Researchers at Peter MacCallum Cancer Centre have developed a digital phenotype to assist with automatically identifying ...

AbbVie today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of upadacitinib (RINVOQ®; 15 ...

News and commentary from the world of gastroenterology and hepatology ...

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved SKYRIZI® (risankizumab) for the treatment of children ...

Positive CHMP opinion is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of Severity of Alopecia Tool (SALT) score = 20 and key ...

The study, published in JAMA Network Open, found the relative risk for inflammatory bowel disease (IBD) was about 8% higher in kids whose mothers took prescription proton pump inhibitors (PPI) or H2 ...

AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for the treatment of children six years of age and older with ...

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of ColoSense®, the only RNA-based at-home test for colorectal ...

In patients with ulcerative colitis exposed to anti-TNF therapy, tofacitinib is linked to higher rates of clinical and ...

Among biologic-naive patients with moderate to severe ulcerative colitis, upadacitinib and infliximab had the quickest onset ...

By Puyaan Singh June 29 (Reuters) - Abivax said on Monday its experimental ulcerative colitis drug helped harder-to-treat groups of patients achieve remission, sending U.S.-listed shares of the ...

Paneth cell metaplasia (PCM), long viewed as a consequence of chronic inflammation in ulcerative colitis, may also help ...